GlassScriptPhysician profile
Ali Homayuni
NPI 1619975026
$7,260.67
in general payments reported to CMS, 2019-2025
36 companies · $271 in 2025
The $271 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,943 · 2020: $283 · 2021: $1,127 · 2022: $1,734 · 2023: $1,263 · 2024: $639 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,083 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,083.12 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $1,308.98 | 2019 | |
| Medtronic, INC. | $871.56 | 2021-2025 | Symplicity G3, Onyx Frontier |
| Novartis Pharmaceuticals Corporation | $783.88 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $743.73 | 2020-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $494.02 | 2019-2024 | Lifevest |
| Medtronic Vascular, INC. | $450.55 | 2019-2020 | |
| Abbott Laboratories | $313.48 | 2021-2024 | Perclose Prostyle, Cardiomems, Diamondback Coronary |
| Amgen INC. | $292.61 | 2019-2025 | Repatha, Repatha |
| Abiomed | $267.65 | 2020-2025 | Impella |
| E.R. Squibb & Sons, L.L.C. | $209.15 | 2020-2025 | Camzyos, Eliquis |
| Pfizer INC. | $185.43 | 2019-2024 | |
| Shockwave Medical, INC | $180.46 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Acist Medical Systems, INC. | $169.00 | 2021 | |
| Penumbra, INC. | $143.88 | 2021-2023 | Indigo System |
| Merck Sharp & Dohme LLC | $111.91 | 2022-2025 | Verquvo |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Homayuni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.